ArticleCancer reports (Hoboken, N.J.)2023

Inetetamab in combination with rapamycin and chemotherapy for trastuzumab-treated metastatic human epidermal growth factor receptor 2-positive breast cancer with abnormal activation of PI3K/Akt/mTOR pathway.

Aijuan Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.